Target intelligence / Profile preview

Nontypeable Haemophilus influenzae Protein D, Protein E, and PilA, and Moraxella catarrhalis Ubiquitous surface protein A2 (NTHi-Mcat Vaccine Antigen Complex)

Target
NTHi-Mcat Vaccine Antigen Complex
Molecular classification
Bacterial surface protein, Antigen, Lipoprotein (Protein D), Adhesin (Protein E, PilA, UspA2), Autotransporter (UspA2)
01

Overview

This target complex consists of four highly conserved surface proteins derived from two major respiratory pathogens: Nontypeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat). Protein D is a highly conserved 42-kDa surface lipoprotein of NTHi that functions as a glycerophosphodiester phosphodiesterase, while Protein E and PilA are involved in adhesion to respiratory epithelial cells and biofilm formation. The Moraxella catarrhalis component, Ubiquitous surface protein A2 (UspA2), is a multifunctional trimeric autotransporter adhesin that plays a critical role in resisting complement-mediated killing and adhering to the extracellular matrix. Together, these proteins serve as the antigenic basis for investigational vaccines designed to prevent acute exacerbations in patients with chronic obstructive pulmonary disease (COPD). By targeting these specific adhesins and virulence factors, the resulting immune response aims to reduce bacterial colonization and the subsequent inflammatory cascade that drives respiratory decline in vulnerable populations.

Other names
NTHi-Mcat antigensProtein D / Protein E / PilA / UspA2GSK3228836A (related vaccine candidate)10-valent pneumococcal conjugate vaccine (contains Protein D)NTHi-Mcat COPD vaccine
02

Mechanism of action

Induction of specific humoral and cellular immune responses, including the production of neutralizing antibodies that inhibit bacterial adhesion and promote opsonophagocytosis of Nontypeable Haemophilus influenzae and Moraxella catarrhalis.

03

Biological functions

Bacterial adhesionColonizationImmune evasionNutrient uptakeBiofilm formation
04

Disease associations

Chronic obstructive pulmonary disease (COPD) exacerbationOtitis mediaInfection
05

Safety considerations

Injection site reactionsFeverMyalgiaPotential for serotype replacementImmunogenicity variability in elderly populations
06

Interacting drugs

GSK3228836A

1 more in the full profile.

07

Biomarkers

Anti-PD antibody titersAnti-PE antibody titersAnti-PilA antibody titersAnti-UspA2 antibody titersSerum bactericidal activity (SBA)

Beyond the preview

Go deeper on Nontypeable Haemophilus influenzae Protein D, Protein E, and PilA, and Moraxella catarrhalis Ubiquitous surface protein A2 (NTHi-Mcat Vaccine Antigen Complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nontypeable Haemophilus influenzae Protein D, Protein E, and PilA, and Moraxella catarrhalis Ubiquitous surface protein A2 (NTHi-Mcat Vaccine Antigen Complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call